Comparative Pharmacology
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus PEPTAVLON.
BREATHTEK UBT FOR H-PYLORI vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREATHTEK UBT is a 13C-urea breath test that detects Helicobacter pylori infection. The patient ingests 13C-labeled urea; if H. pylori is present, its urease enzyme hydrolyzes urea to 13CO2, which is absorbed and exhaled, allowing detection by mass spectrometry or infrared spectroscopy.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
75 mg of 13C-urea oral powder dissolved in 75 mL water, administered once after a baseline breath sample; a second breath sample is collected 30 minutes after dosing.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
13C-urea has a plasma half-life of approximately 0.5–1 hour. The 13CO2 exhaled peak occurs at 20–30 minutes, reflecting rapid urease hydrolysis. The terminal half-life is not clinically relevant as the breath test relies on early exhalation kinetics.
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
BreathTek UBT (13C-urea) is metabolized by H. pylori urease to 13CO2, which is exhaled. Unmetabolized urea is renally excreted; renal elimination of unchanged 13C-urea accounts for approximately 20-30% of the administered dose, with the remainder exhaled as 13CO2 within 60 minutes. Fecal/biliary excretion is negligible.
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent